Cardiovascular
Myocardial Fibrosis
13
Pipeline Programs↗
4
Active Trials↗
6
Companies Involved↗
Myocardial fibrosis is an emerging landscape with 13 programs across 6 companies. The most active players are Pfizer, AstraZeneca, Novartis. 7 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 21
Phase 33
Analysis
Trial Status
9
clinical trials
Completed4 · 44%
Recruiting2 · 22%
Not yet recruiting2 · 22%
Unknown status1 · 11%
Clinical Trials
Trial Activity
9 trials
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
Recruiting·—·Phase 2·NCT05012631·24 enrolled
Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Not yet recruiting·—·Phase 4·NCT06536309·36 enrolled
Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.
Completed·—·Phase 4·NCT00409942·142 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)